| Name | Title | Contact Details |
|---|
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.
Selventa is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.
Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We are dedicated to developing innovative medicines for patients. It is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care.